Vera Therapeutics (VERA) news
Recent news
Wedbush cuts target price to $34 from $43 for Vera Therapeutics, Inc.
Wedbush Securities has revised its price target for Vera Therapeutics, Inc. (VERA), reducing it from $43 to $34, according to recent reports. The adjustment reflects the firm’s updated assessment of the company’s clinical and operational progress, particularly regarding the enrollment status of its…
AInvest Wire · Aug 11, 2026Vera Therapeutics Q2 EPS USD -1.52 vs. IBES estimate USD -1.56 (corrects amount)
AInvest Wire · Aug 10, 2026Vera Therapeutics Q2 EPS USD 1.52 vs. IBES estimate USD -1.56
Vera Therapeutics, Inc. (NASDAQ: VERA) reported its Q2 2026 earnings on August 10, 2026, with an earnings per share (EPS) of -$1.52, which exceeded the IBES estimate of -$1.56 by $0.04. This result marked an improvement compared to the previous quarter, where the company reported EPS of -$1.69 ,…
AInvest Wire · Aug 10, 2026Vera Therapeutics anticipates SBLA submission to FDA for Trutakna in Q4 2026
AInvest Wire · Aug 10, 2026Vera Therapeutics announces appointment of Nancy Boman as chief regulatory officer and planned retirement of William Turner
AInvest Wire · Jul 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.